An optimized cyclophosphamide-treated mouse model of <i>Mycobacterium abscessus</i> pulmonary infection-Reference-Cited by-同舟云学术

An optimized cyclophosphamide-treated mouse model of Mycobacterium abscessus pulmonary infection

Published:2024-08-07 Issue:8 Volume:68 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Sun Yan¹,Zhang Kaixi²,Delos Santos May²,Pee Carmen J. E.¹³,Yang Yanmeng⁴,Kang Meiqi⁴,Shin Sung Jae⁵^ORCID,Chan-Park Mary B.¹⁶⁷,Pethe Kevin¹²⁸⁹^ORCID

Affiliation:

1. Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore

2. Antimicrobial Resistance Interdisciplinary Research Group, Singapore-MIT Alliance for Research and Technology Centre, Singapore, Singapore

3. Interdisciplinary Graduate Programme, Nanyang Technological University, Singapore, Singapore

4. Critical Analytics for Manufacturing of Personalized Medicine (CAMP) Interdisciplinary Research Group, Singapore-MIT Alliance for Research and Technology Centre, Singapore, Singapore

5. Department of Microbiology, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, South Africa

6. Chemical Engineering and Biotechnology, Nanyang Technological University, Singapore, Singapore

7. Centre for Antimicrobial Bioengineering, Nanyang Technological University, Singapore, Singapore

8. Singapore Centre for Environmental Life Sciences Engineering, Nanyang Technological University, Singapore, Singapore

9. National Centre for Infectious Diseases, Singapore, Singapore

Abstract

ABSTRACT Mycobacterium abscessus pulmonary infections are increasingly problematic, especially for immunocompromised individuals and those with underlying lung conditions. Currently, there is no reliable standardized treatment, underscoring the need for improved preclinical drug testing. We present a simplified immunosuppressed mouse model using only four injections of cyclophosphamide, which allows for sustained M. abscessus lung burden for up to 16 days. This model proved effective for antibiotic efficacy evaluation, as demonstrated with imipenem or amikacin.

Funder

Ministry of Education - Singapore

National Research Foundation Singapore

Publisher

American Society for Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.01520-23

Reference21 articles.

1. Epidemiology of infection by nontuberculous mycobacteria

2. The Epidemiology of Disseminated Nontuberculous Mycobacterial Infection in the Acquired Immunodeficiency Syndrome (AIDS)

3. Nontuberculous Mycobacteria in Cystic Fibrosis and Non–Cystic Fibrosis Bronchiectasis

4. Immune defects in patients with pulmonary Mycobacterium abscessus disease without cystic fibrosis

5. Clinical Efficacy and Adverse Effects of Antibiotics Used to Treat Mycobacterium abscessus Pulmonary Disease